Final-Program-ATS-2023-AP.vp

310

WEDNESDAY • MAY 24

Target Audience Pulmonary providers, pharmacists, pulmonary rehabilitation providers, and health policy makers who care for older adults with chronic lung diseases Objectives At the conclusion of this session, the participant will be able to: • define the components of age-friendly healthcare (4Ms) in chronic lung disease • apply the 4M framework and understanding of the physiology of aging to adapt diagnostic testing algorithms and treatment protocols for older adults with and without geriatric syndromes • identify geriatrics assessments that should be routinely performed by pulmonologists or assessed by these experts prior to making diagnosis or treatment decisions for chronic lung diseases Older adults are disproportionately affected by many chronic lung diseases (e.g. COPD, asthma, bronchiectasis). Developing diagnostic and treatment strategies for older adults in an age-friendly health system must consider diagnostic accuracy, likelihood of benefit, and the unique needs of this population. The John A. Hartford Foundation and the Institute for Healthcare Improvement have outlined a conceptual framework for age-friendly healthcare delivery called the 4Ms – Medication, Mobility, Mentation, and What Matters. The proposed symposium includes a diverse group of interprofessional and international experts in aging who will highlight the impact this framework has on caring for patients with chronic lung disease. Chairing: M.F. Griffith, MD, MPH, Aurora, CO L.J. Witt, MD, San Francisco, CA A.S. Iyer, MD, MSPH, Birmingham, AL S. Jain, MD, New Haven, CT 8:00 Public Advisory Roundtable Presentation 8:10 Overview of The Age-Friendly Health System (4M) Framework M. Bellantoni, MD, Baltimore, MD 8:22 Biology of Lung Aging S. Krick, MD, PhD, Birmingham, AL 8:34 Diagnostic Dilemmas in Chronic Lung Disease for the Older Adult J. Hurst, MD, London, United Kingdom 8:46 Pharmacotherapy in the Older Adult with Chronic Lung Disease A.L. Martirosov, PharmD, Detroit, MI 8:58 Frailty, Falls and Chronic Lung Disease A.M. Yohannes, PhD, ATSF, Azusa, CA 9:10 Caring for Chronic Lung Disease Patients in Nursing Homes M.F. Griffith, MD, MPH, Aurora, CO

9:22 Moderated Q&A by Chairs This session and the International Conference are supported by an independent medical educational grant from AstraZeneca LP, and Insmed Incorporated. All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

D11

THE EVOLVING ROLE FOR IMMUNOTHERAPY IN LUNG CANCER

Assembly on Thoracic Oncology 8:00 AM - 9:30 AM

Marriott Marquis Washington Liberty Ballroom, Salons M-P (Level M-4 )

Target Audience Clinicians and researchers who care for thoracic oncology patients Objectives At the conclusion of this session, the participant will be able to: • understand how immune checkpoint inhibitors are used to treat lung cancer • summarize recent updates in cancer immunotherapy for lung cancer • describe management approaches for difficult or refractory immune-related adverse events Our understanding of the role of the immune system in lung cancer has changed dramatically over the past couple decades. Immune checkpoint inhibitors have revolutionized the treatment of lung cancer, leading to durable responses in a subset of non-small cell lung cancer patients. However, many patients with lung cancer fail to respond or develop resistance to immune checkpoint inhibitors, highlighting the need for novel immunotherapies. Immune checkpoint inhibitors are also associated with toxicities that will be managed by pulmonologists and intensivists, such as pneumonitis. The speakers, all world-class experts in lung immuno-oncology, will provide perspective on this quickly evolving field. Chairing: S. Shojaee, MD, MPH, Nashville, TN J. Deepak, MD, MBBS, FACP, Baltimore, MD M. Acunzo, PhD, Richmond, VA 8:00 Introduction S. Shojaee, MD, MPH, Nashville, TN 8:05 Immune Dynamics During Lung Cancer Development, from Premalignant to Invasive S.M. Dubinett, MD, Los Angeles, CA

ATS 2023 • Washington, DC